FTRE Price Prediction Next Week
Analysis and Insights
Technical Analysis:
The stock price of FTRE is currently showing bearish momentum. The Relative Strength Index (RSI) is at 29.18, indicating oversold conditions, while the MACD is negative, suggesting downward momentum. The Fibonacci levels indicate a pivot point at $9.53, with resistance levels at $10.21 and $10.64.
News Sentiment and Analyst Ratings:
Analysts have lowered their price targets for FTRE, with TD Cowen reducing it from $20 to $11 and BofA lowering it to $10. The average consensus price target is $15.40, but recent adjustments reflect a cautious outlook due to disappointing Q4 results and ongoing growth challenges.
Price Prediction:
Based on the technical indicators and analyst sentiment, the stock is expected to trade around $9.50 in the next trading week. The bearish trend and negative news sentiment suggest a sell recommendation.
Conclusion:
Sell FTRE at the current price of $9.30, targeting a price of $9.50 in the next trading week.
FTRE Similar Chart Price Prediction
The price of FTRE is predicted to go up 50.16%, based on the high correlation periods with EVER. The similarity of these two price pattern on the periods is 99.4%.
FTRE
EVER
Up: 50.16%Similarity: 99.4%
FTRE Revenue Forecast
FTRE EPS Forecast
FTRE FAQs
What is FTRE revenue forecast for next quarter？
What is FTRE eps forecast for next quarter？
FTRE VS S&P500
Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.
Fortrea has extensive experience across 20 therapeutic areas across every phase of the development from clinical pharmacology to phase 4 studies conducted post-approval.
Fortrea has a large global footprint with operations in 90 countries, which is beneficial when running late-stage, multinational clinical trials.
FTRE Analyst's Forecast
Luke Sergott
Barclays
Hold
2025-03-04
Price Target
$25 → $12
Upside
+9.49%
Barclays lowered the firm's price target on Fortrea to $12 from $25 and keeps an Equal Weight rating on the shares.
Patrick Donnelly
Citigroup
Strong Buy → Hold
2024-12-11
Price Target
$30 → $23
Upside
+18.25%
Eric Coldwell
Baird
Buy → Hold
2024-12-06
Price Target
$28 → $25
Upside
+15.37%
